5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity

Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with these medicines.

Flucytosine (Ancotil): new contraindication in patients with DPD deficiency

Flucytosine is a prodrug of 5-fluorouracil used to treat systemic yeast and fungal infections and can cause life-threatening and severe toxicity in patients with complete and partial dihydropyrimidine dehydrogenase (DPD) def…

Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment

Increase the frequency of blood pressure monitoring to at least weekly for the first 2 months, and then monitor monthly for the first year and periodically thereafter during treatment, following recent reports of onset of se…

Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects

Updated safety recommendations have been issued as part of the European review evaluating cases of neural tube defects in babies born to mothers who became pregnant while taking the HIV medicine dolutegravir.

Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic

Guidance has been published on monitoring of patients on warfarin and other anticoagulants during the COVID-19 pandemic.

Every report counts: report suspected adverse drug reactions and take part in #MedSafetyWeek (2–8 November 2020)

Remain vigilant for suspected adverse drug reactions and report them to the Yellow Card scheme.

Letters and drug alerts sent to healthcare professionals in September 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Posted on the UK MHRA website on 22 October 2020